Chapter 29 - Clinical neurophysiology of postural tachycardia syndrome
Introduction
Postural tachycardia syndrome (POTS) is one of several disorders of orthostatic intolerance (OI), including neurocardiogenic or vasovagal syncope and neurogenic orthostatic hypotension (nOH). OI is defined as symptoms of cerebral hypoperfusion or sympathetic activation that develop with upright posture and are relieved with recumbency. POTS is defined as a symptomatic and sustained heart-rate increment of 30 beats/min or more within 10 min of standing or head-up tilt in the absence of OH; the standing heart rate is often 120 beats/min or higher (Freeman et al., 2011; Sheldon et al., 2015). An orthostatic increment of 30 beats/min exceeded the 99th percentile of 271 control subjects aged 10–83 years (Low et al., 1997). For individuals aged 12–19 years, the required increment is at least 40 beats/min (Freeman et al., 2011; Singer et al., 2012). Diagnostic criteria have not been established for younger children.
The current definition of POTS focuses on symptoms and heart-rate increment induced by postural changes. The focus on orthostatic tachycardia is appropriate because an excessive rise in heart rate is the earliest and most consistent of the readily measured indices of OI (Streeten, 1987).
Section snippets
Demographics
The typical age of presentation is between 15 and 50 years (Schondorf and Low, 1993; Thieben et al., 2007). Early studies suggested men and women were affected equally (Fouad et al., 1986; Hoeldtke et al., 1989), but the preponderance of more recent work has shown an overrepresentation of women (Rosen and Cryer, 1982; Schondorf and Low, 1993; Low et al., 1994; Thieben et al., 2007) at a ratio of approximately 5:1.
Symptoms
Symptoms of cerebral hypoperfusion that may occur with any of the OI disorders include lightheadedness, dizziness, presyncope, blurred vision, generalized weakness, and cognitive difficulties. Symptoms of sympathoexcitation include palpitations, chest pain, shortness of breath, tremulousness, nausea, diarrhea, pallor, sweating, and coldness of the extremities. Approximately one-third of patients with POTS also experience posturally triggered vasovagal syncope (Al-Shekhlee et al., 2008).
Clinical Examination
The neurologic examination in patients with POTS is normal, with rare exception. Supine and standing vital signs will show an excessive heart-rate increment without blood pressure drop, though pulse pressure may be excessively reduced. Palpating the radial pulse may become more difficult with continued standing or with the performance of a Valsalva maneuver (Flack sign). Prolonged standing may also be associated with coldness, blueness, or swelling of the hands and feet (Streeten, 1987).
Pathophysiology
POTS is not one disorder but rather a heterogeneous syndrome resulting from several distinct pathophysiologic mechanisms that are not mutually exclusive (Sandroni et al., 1999; Jacob et al., 2000; Stewart and Montgomery, 2004; Nickander et al., 2005; Medow and Stewart, 2007; Garland et al., 2007b; Carew et al., 2009; Low et al., 2009; Parsaik et al., 2012). The main POTS mechanisms are impaired sympathetically mediated vasoconstriction in the lower limbs (neuropathic POTS), excessive cardiac
Comorbidities
Many patients with POTS have additional chronic conditions. These comorbidities may include visceral hypersensitivity, gastrointestinal dysmotility, chronic fatigue, insomnia, fibromyalgia, headaches, joint hypermobility, mitral valve prolapse (MVP), and inappropriate sinus tachycardia (IST).
Differential Diagnosis
In addition to the causes of OI already discussed (anxiety/panic, CFS, fibromyalgia, EDS, MVP), the differential diagnosis of POTS also includes nOH, constitutional OI, cerebrospinal fluid (CSF) leak, and median arcuate ligament syndrome.
Evaluation
The evaluation of a patient suspected of having POTS is necessarily multidisciplinary and should begin with a complete history and physical examination. The history should focus on the timing of onset and progression of orthostatic symptoms, presence of nonorthostatic symptoms, precipitating and aggravating factors, fluid and caffeine intake, level of physical activity and standing time, response to previously attempted treatments, and current drug therapy (Low et al., 2009; Mathias et al., 2011
Management
The objectives of POTS management are to (1) increase the time that patients can stand, perform daily activities, and exercise and (2) avoid syncope. Management involves nonpharmacologic (Table 29.3) and pharmacologic (Table 29.4) approaches. Patient education about POTS is fundamental and should include review of potential aggravating or precipitating factors of orthostatic and exercise intolerance. Few treatments have been subjected to the rigor of randomized clinical trials, and consensus is
Prognosis
Data are limited on the long-term prognosis of POTS. In one large cross-sectional study that used a validated autonomic symptom profile at initial evaluation and a structured autonomic questionnaire at prospective follow-up at least 18 months later, 80% of patients were improved, 90% were able to return to work, and 60% were functionally normal (Sandroni et al., 1999). Salt supplementation and β-blockers were the most efficacious therapies. In another prospective follow-up study, 70% of
Future Directions
Recent work has shown not only impaired quality of life measures but also increased thoughts of suicide in patients with POTS (Pederson and Brook, 2017). Such findings highlight the importance of further elucidating the causes and mechanisms of POTS, as well as ongoing work to develop more effective treatments.
References (150)
Postural tachycardia syndrome: a heterogeneous and multifactorial disorder
Mayo Clin Proc
(2012)- et al.
Quality of life in patients with postural tachycardia syndrome
Mayo Clin Proc
(2002) - et al.
Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation
Mayo Clin Proc
(1996) - et al.
Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation
J Am Coll Cardiol
(2012) - et al.
A multicenter study on treatment of autonomous nerve-mediated syncope in children with beta-receptor blocker
Zhonghua Er Ke Za Zhi
(2007) - et al.
The science of fibromyalgia
Mayo Clin Proc
(2011) - et al.
Dysautonomia in mitral valve prolapse
Am J Med
(1979) - et al.
Mitral valve prolapse with symptoms of beta-adrenergic hypersensitivity. Beta 2-adrenergic receptor supercoupling with desensitization on isoproterenol exposure
Am J Med
(1987) - et al.
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome
Auton Neurosci
(2011) - et al.
Cardiac origins of the postural orthostatic tachycardia syndrome
J Am Coll Cardiol
(2010)
Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia
Chest
Chiari I malformation as a cause of orthostatic intolerance symptoms: a media myth?
Am J Med
Dysautonomia in the joint hypermobility syndrome
Am J Med
Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system
Am J Med
Effects of standing on cerebrovascular resistance in patients with idiopathic orthostatic intolerance
Am J Med
Interaction of genetic predisposition and environmental factors in the pathogenesis of idiopathic orthostatic intolerance
Am J Med Sci
The impact of chronic primary insomnia on the heart rate-EEG variability link
Clin Neurophysiol
A prospective, 1-year follow-up study of postural tachycardia syndrome
Mayo Clin Proc
Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure
J Auton Nerv Syst
Orthostatic intolerance and the headache patient
Semin Pediatr Neurol
A screen of candidate genes and influence of beta2-adrenergic receptor genotypes in postural tachycardia syndrome
Auton Neurosci
Comorbidities in pediatric patients with postural orthostatic tachycardia syndrome
J Pediatr
Heart rate and plasma cyclic AMP responses to isoproterenol infusion and effect of beta-adrenergic blockade in patients with postural orthostatic tachycardia syndrome
J Cardiovasc Pharmacol
Upper functional gastrointestinal disorders in young adults
Med Arh
Postural tachycardia syndrome with asystole on head-up tilt
Clin Auton Res
The value of autonomic testing in postural tachycardia syndrome
Clin Auton Res
Sleep disturbances and diminished quality of life in postural tachycardia syndrome
J Clin Sleep Med
The effects of a poor night sleep on mood, cognitive, autonomic and electrophysiological measures
J Integr Neurosci
The effect of Ivabradine on the heart rate and Sympathovagal balance in postural tachycardia syndrome patients
Rambam Maimonides Med J
Mitral valve prolapse syndrome. Evidence of hyperadrenergic state
Postgrad Med
The relationship between neurally mediated hypotension and the chronic fatigue syndrome
JAMA
Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence
Arch Gen Psychiatry
Inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, and overlapping syndromes
Pacing Clin Electrophysiol
A review of postural orthostatic tachycardia syndrome
Europace
Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes
Neurology
Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases
Clin Auton Res
Mitral valve prolapse: causes, clinical manifestations, and management
Ann Intern Med
Functional dizziness: from phobic postural vertigo and chronic subjective dizziness to persistent postural-perceptual dizziness
Curr Opin Neurol
Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope
Heart
Acute volume loading and exercise capacity in postural tachycardia syndrome
J Appl Physiol (1985)
A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress
J Appl Physiol (1985)
Idiopathic hypovolemia
Ann Intern Med
Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone
Clin Auton Res
Menstrual cycle affects renal-adrenal and hemodynamic responses during prolonged standing in the postural orthostatic tachycardia syndrome
Hypertension
Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome
Hypertension
The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group
Ann Intern Med
Management and pathophysiology of functional gastrointestinal disorders
Digestion
Dopamine-beta-hydroxylase in postural tachycardia syndrome
Am J Physiol Heart Circ Physiol
The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome
Neurology
Exercise performance and fatiguability in patients with chronic fatigue syndrome
J Neurol Neurosurg Psychiatry
Cited by (17)
The concomitant diagnosis of fibromyalgia and connective tissue disorders: A systematic review
2023, Seminars in Arthritis and RheumatismCitation Excerpt :A total of 61 studies were excluded based on the title and abstract, and 24 studies remained for full text reading. Of these, thirteen studies were excluded [2,41-52]. The final review included eleven studies [1,5-7,24-30].
Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment
2020, Progress in Cardiovascular DiseasesCitation Excerpt :These commonly include: fludrocortisone, midodrine, modafinil, vasopressin, serotonin reuptake inhibitors, yohimbine, methylphenidate, alpha methyl-dopa, clonidine, phenobarbital, octreotide, and beta-blockers. The use of such drugs has been reported72–83 but prospective controlled studies supporting long-term benefit are lacking. Perhaps the therapeutic intervention with the most supportive data is low-dose propranolol84 since this has been relatively well-tested versus placebo although it did not perform as well as cardiovascular exercise.58
Subcategories of Fibromyalgia-A New Concept
2023, Current Rheumatology ReviewsClinical phenotype of postural orthostatic tachycardia associated with anti-adrenergic receptor antibodies
2023, Gaceta Medica de BilbaoResting heart rate variability as a diagnostic marker of cardiovascular dysautonomia in postural tachycardia syndrome
2023, Journal of Basic and Clinical Physiology and Pharmacology